Basilea Pharmaceutica Release: FDA Accepts for Review the Complete Response to Ceftobiprole NDA Approvable Letter

September 15, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

BASEL, SWITZERLAND--(Marketwire - September 15, 2008) - Basilea Pharmaceutica Ltd. announces that the Food and Drug Administration (FDA) has accepted for review the Complete Response to the ceftobiprole New Drug Application (NDA) Approvable Letter.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory Europe

Food and Drug Administration (FDA)